{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:31:14Z","timestamp":1785335474701,"version":"3.55.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41417-026-01040-9","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:47:33Z","timestamp":1781596053000},"page":"492-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reprogramming the tumor microenvironment via TFF3 targeting: a potential novel avenue to boost CAR-T cell therapy in solid tumors"],"prefix":"10.1038","volume":"33","author":[{"given":"Arman","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasem","family":"Solgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnoush","family":"Safarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantea","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-9920","authenticated-orcid":false,"given":"Mohsen","family":"Rastegari-Pouyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1040_CR1","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1245\/s10434-018-6658-4","volume":"25","author":"T Pham","year":"2018","unstructured":"Pham T, Roth S, Kong J, Guerra G, Narasimhan V, Pereira L, et al. An update on immunotherapy for solid tumors: a review. Ann Surg Oncol. 2018;25:3404\u201312.","journal-title":"Ann Surg Oncol"},{"key":"1040_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"1040_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"1040_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jha2.356","volume":"3","author":"U Patel","year":"2022","unstructured":"Patel U, Abernathy J, Savani BN, Oluwole O, Sengsayadeth S, Dholaria B. CAR T cell therapy in solid tumors: a review of current clinical trials. EJHaem. 2022;3:24\u201331.","journal-title":"EJHaem"},{"key":"1040_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen T, Wang M, Chen Y, Liu Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 2024;24:133.","journal-title":"Cancer Cell Int"},{"key":"1040_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther Oncolytics. 2022;25:69\u201377.","journal-title":"Mol Ther Oncolytics"},{"key":"1040_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103534","volume":"81","author":"DN Elmaci","year":"2025","unstructured":"Elmaci DN, Hopping G, Hoffmann W, Muttenthaler M, Stein M. The structural integrity of human TFF1 under reducing conditions. Redox Biol. 2025;81:103534.","journal-title":"Redox Biol"},{"key":"1040_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298186","volume":"14","author":"M Wang","year":"2023","unstructured":"Wang M, Shi J, Yu C, Zhang X, Xu G, Xu Z, et al. Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? Front Immunol. 2023;14:1298186.","journal-title":"Front Immunol"},{"key":"1040_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-016-0379-1","volume":"17","author":"Z Yuan","year":"2017","unstructured":"Yuan Z, Chen D, Chen X, Yang H, Wei Y. Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells. Cancer Cell Int. 2017;17:7.","journal-title":"Cancer Cell Int"},{"key":"1040_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2016.106","volume":"3","author":"C Hanisch","year":"2017","unstructured":"Hanisch C, Sharbati J, Kutz-Lohroff B, Huber O, Einspanier R, Sharbati S. TFF3-dependent resistance of human colorectal adenocarcinoma cells HT-29\/B6 to apoptosis is mediated by miR-491-5p regulation of lncRNA PRINS. Cell Death Discov. 2017;3:16106.","journal-title":"Cell Death Discov"},{"key":"1040_CR11","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger K, Schmid S, Paulsen F, Ignatius A, Klinger P, Hotfiel T, et al. Trefoil factor 3 (TFF3) Is Involved in Cell Migration for Skeletal Repair. Int J Mol Sci. 2019;20:4277.","DOI":"10.3390\/ijms20174277"},{"key":"1040_CR12","doi-asserted-by":"publisher","first-page":"6472","DOI":"10.1158\/1078-0432.CCR-05-0671","volume":"11","author":"DK Dhar","year":"2005","unstructured":"Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res. 2005;11:6472\u20138.","journal-title":"Clin Cancer Res"},{"key":"1040_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ajpath.2011.11.022","volume":"180","author":"ARH Ahmed","year":"2012","unstructured":"Ahmed ARH, Griffiths AB, Tilby MT, Westley BR, May FEB. TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol. 2012;180:904\u201316.","journal-title":"Am J Pathol"},{"key":"1040_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1158\/1055-9965.EPI-21-0760","volume":"31","author":"X Zan","year":"2022","unstructured":"Zan X, Chen Z, Guo Q, Wang Y, Zhang Z, Ji R, et al. The association of trefoil factors with gastric cancer and premalignant lesions: a cross-sectional population-based cohort study. Cancer Epidemiol Biomark Prev. 2022;31:625\u201332.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1040_CR15","first-page":"789","volume":"55","author":"A Yusufu","year":"2019","unstructured":"Yusufu A, Shayimu P, Tuerdi R, Fang C, Wang F, Wang H. TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process. Int J Oncol. 2019;55:789\u2013804.","journal-title":"Int J Oncol"},{"key":"1040_CR16","first-page":"1","volume":"50","author":"J Liu","year":"2018","unstructured":"Liu J, Kim SY, Shin S, Jung S-H, Yim S-H, Lee JY, et al. Overexpression of TFF3 is involved in prostate carcinogenesis via blocking mitochondria-mediated apoptosis. Exp Mol Med. 2018;50:1\u201311.","journal-title":"Exp Mol Med"},{"key":"1040_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3892\/ol.2023.13725","volume":"25","author":"K Minegishi","year":"2023","unstructured":"Minegishi K, Dobashi Y, Koyama T, Ishibashi Y, Furuya M, Tsubochi H, et al. Diagnostic utility of trefoil factor families for the early detection of lung cancer and their correlation with tissue expression. Oncol Lett. 2023;25:139.","journal-title":"Oncol Lett"},{"key":"1040_CR18","doi-asserted-by":"crossref","unstructured":"Poh HM, Chiou YS, Chong QY, Chen RM, Rangappa KS, Ma L, et al. Inhibition of TFF3 enhances sensitivity and overcomes acquired resistance to doxorubicin in estrogen receptor-positive mammary carcinoma. Cancers. 2019;11:1528.","DOI":"10.3390\/cancers11101528"},{"key":"1040_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.mucimm.2024.02.003","volume":"17","author":"LM Ethgen","year":"2024","unstructured":"Ethgen LM, Pastore C, Lin C, Reed DR, Hung LY, Douglas B, et al. A Trefoil factor 3-Lingo2 axis restrains proliferative expansion of type-1 T helper cells during GI nematode infection. Mucosal Immunol. 2024;17:238\u201356.","journal-title":"Mucosal Immunol"},{"key":"1040_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123113","volume":"357","author":"P Huang","year":"2024","unstructured":"Huang P, Wolde T, Bhardwaj V, Zhang X, Pandey V. TFF3 and PVRL2 co-targeting identified by multi-omics approach as an effective cancer immunosuppression strategy. Life Sci. 2024;357:123113.","journal-title":"Life Sci"},{"key":"1040_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108581","volume":"106","author":"M Rastegari-Pouyani","year":"2022","unstructured":"Rastegari-Pouyani M, Mohammadi-Motlagh HR, Baghaei K, Mansouri K, Hajivalili M, Mostafaie A, et al. 2-methylpyridine-1-ium-1-sulfonate modifies tumor-derived exosome-mediated macrophage polarization: Relevance to the tumor microenvironment. Int Immunopharmacol. 2022;106:108581.","journal-title":"Int Immunopharmacol"},{"key":"1040_CR22","doi-asserted-by":"publisher","first-page":"11149","DOI":"10.1002\/cam4.5698","volume":"12","author":"Q Wang","year":"2023","unstructured":"Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023;12:11149\u201365.","journal-title":"Cancer Med"},{"key":"1040_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","volume":"15","author":"KC Valkenburg","year":"2018","unstructured":"Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366\u201381.","journal-title":"Nat Rev Clin Oncol"},{"key":"1040_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15404-8","volume":"11","author":"AJ Gunderson","year":"2020","unstructured":"Gunderson AJ, Yamazaki T, McCarty K, Fox N, Phillips M, Alice A, et al. TGF\u03b2 suppresses CD8(+) T cell expression of CXCR3 and tumor trafficking. Nat Commun. 2020;11:1749.","journal-title":"Nat Commun"},{"key":"1040_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18:195\u2013203.","journal-title":"Nat Rev Immunol"},{"key":"1040_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"1040_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12672-023-00793-1","volume":"14","author":"ZN He","year":"2023","unstructured":"He ZN, Zhang CY, Zhao YW, He SL, Li Y, Shi BL, et al. Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer. Discov Oncol. 2023;14:185.","journal-title":"Discov Oncol"},{"key":"1040_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","volume":"7","author":"K Bardhan","year":"2016","unstructured":"Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1\/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550.","journal-title":"Front Immunol"},{"key":"1040_CR29","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","volume":"20","author":"EK Moon","year":"2014","unstructured":"Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res. 2014;20:4262\u201373.","journal-title":"Clin Cancer Res"},{"key":"1040_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298683","volume":"14","author":"J He","year":"2023","unstructured":"He J, Yan Y, Zhang J, Wei Z, Li H, Xing L. Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors. Front Immunol. 2023;14:1298683.","journal-title":"Front Immunol"},{"key":"1040_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4049\/jimmunol.1701155","volume":"200","author":"S Srivastava","year":"2018","unstructured":"Srivastava S, Riddell SR. Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J Immunol. 2018;200:459\u201368.","journal-title":"J Immunol"},{"key":"1040_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","volume":"45","author":"B Bengsch","year":"2016","unstructured":"Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity. 2016;45:358\u201373.","journal-title":"Immunity"},{"key":"1040_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.semcancer.2012.03.002","volume":"22","author":"K Sampieri","year":"2012","unstructured":"Sampieri K, Fodde R. Cancer stem cells and metastasis. Semin Cancer Biol. 2012;22:187\u201393.","journal-title":"Semin Cancer Biol"},{"key":"1040_CR34","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s12015-022-10426-9","volume":"18","author":"A Nayak","year":"2022","unstructured":"Nayak A, Warrier NM, Kumar P. Cancer stem cells and the tumor microenvironment: targeting the critical crosstalk through nanocarrier systems. Stem Cell Rev Rep. 2022;18:2209\u201333.","journal-title":"Stem Cell Rev Rep"},{"key":"1040_CR35","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/carcin\/bgac035","volume":"43","author":"W Zhao","year":"2022","unstructured":"Zhao W, Lv M, Yang X, Zhou J, Xing B, Zhang Z. Liver tumor-initiating cells initiate the formation of a stiff cancer stem cell microenvironment niche by secreting LOX. Carcinogenesis. 2022;43:766\u201378.","journal-title":"Carcinogenesis"},{"key":"1040_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-018-0426-4","volume":"25","author":"AZ Ayob","year":"2018","unstructured":"Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25:20.","journal-title":"J Biomed Sci"},{"key":"1040_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther. 2024;9:170.","journal-title":"Signal Transduct Target Ther"},{"key":"1040_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.692940","volume":"9","author":"MML Lei","year":"2021","unstructured":"Lei MML, Lee TKW. Cancer stem cells: emerging key players in immune evasion of cancers. Front Cell Dev Biol. 2021;9:692940.","journal-title":"Front Cell Dev Biol"},{"key":"1040_CR39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13287-024-04061-z","volume":"15","author":"Q Li","year":"2024","unstructured":"Li Q, He G, Yu Y, Li X, Peng X, Yang L. Exosome crosstalk between cancer stem cells and tumor microenvironment: cancer progression and therapeutic strategies. Stem Cell Res Ther. 2024;15:449.","journal-title":"Stem Cell Res Ther"},{"key":"1040_CR40","doi-asserted-by":"publisher","first-page":"36137","DOI":"10.18632\/oncotarget.16661","volume":"8","author":"X Sun","year":"2017","unstructured":"Sun X, Ma X, Wang J, Zhao Y, Wang Y, Bihl JC, et al. Glioma stem cell-derived exosomes promote the angiogenic ability of endothelial cells through miR-21\/VEGF signal. Oncotarget. 2017;8:36137\u201348.","journal-title":"Oncotarget"},{"key":"1040_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2017.1359479","volume":"6","author":"L Treps","year":"2017","unstructured":"Treps L, Perret R, Edmond S, Ricard D, Gavard J. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J Extracell Vesicles. 2017;6:1359479.","journal-title":"J Extracell Vesicles"},{"key":"1040_CR42","doi-asserted-by":"publisher","first-page":"e0279400","DOI":"10.1371\/journal.pone.0279400","volume":"18","author":"P Gonz\u00e1lez-Callejo","year":"2023","unstructured":"Gonz\u00e1lez-Callejo P, Guo Z, Ziglari T, Claudio NM, Nguyen KH, Oshimori N, et al. Cancer stem cell-derived extracellular vesicles preferentially target MHC-II-macrophages and PD1+ T cells in the tumor microenvironment. PLoS ONE. 2023;18:e0279400.","journal-title":"PLoS ONE"},{"key":"1040_CR43","doi-asserted-by":"publisher","first-page":"15139","DOI":"10.1021\/bi030182k","volume":"42","author":"FW Muskett","year":"2003","unstructured":"Muskett FW, May FE, Westley BR, Feeney J. Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry. 2003;42:15139\u201347.","journal-title":"Biochemistry"},{"key":"1040_CR44","doi-asserted-by":"publisher","first-page":"9484","DOI":"10.1021\/acs.jmedchem.1c00767","volume":"64","author":"N Braga Emidio","year":"2021","unstructured":"Braga Emidio N, Meli R, Tran HNT, Baik H, Morisset-Lopez S, Elliott AG, et al. Chemical synthesis of TFF3 reveals novel mechanistic insights and a gut-stable metabolite. J Med Chem. 2021;64:9484\u201395.","journal-title":"J Med Chem"},{"key":"1040_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41419-022-04700-4","volume":"13","author":"F Cheng","year":"2022","unstructured":"Cheng F, Wang X, Chiou Y-S, He C, Guo H, Tan YQ, et al. Trefoil factor 3 promotes pancreatic carcinoma progression via WNT pathway activation mediated by enhanced WNT ligand expression. Cell Death Dis. 2022;13:265.","journal-title":"Cell Death Dis"},{"key":"1040_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12315-1","volume":"10","author":"NM Belle","year":"2019","unstructured":"Belle NM, Ji Y, Herbine K, Wei Y, Park J, Zullo K, et al. TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. Nat Commun. 2019;10:4408.","journal-title":"Nat Commun"},{"key":"1040_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21834-8","volume":"8","author":"AM Duraj-Thatte","year":"2018","unstructured":"Duraj-Thatte AM, Praveschotinunt P, Nash TR, Ward FR, Nguyen PQ, Joshi NS. Modulating bacterial and gut mucosal interactions with engineered biofilm matrix proteins. Sci Rep. 2018;8:3475.","journal-title":"Sci Rep"},{"key":"1040_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.tibs.2019.01.004","volume":"44","author":"N Braga Emidio","year":"2019","unstructured":"Braga Emidio N, Hoffmann W, Brierley SM, Muttenthaler M. Trefoil factor family: unresolved questions and clinical perspectives. Trends Biochem Sci. 2019;44:387\u201390.","journal-title":"Trends Biochem Sci"},{"key":"1040_CR49","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.3390\/ijms222312828","volume":"22","author":"W-L Cheng","year":"2021","unstructured":"Cheng W-L, Feng P-H, Lee K-Y, Chen K-Y, Sun W-L, Van Hiep N, et al. The role of EREG\/EGFR pathway in tumor progression. Int J Mol Sci. 2021;22:12828.","journal-title":"Int J Mol Sci"},{"key":"1040_CR50","first-page":"332","volume":"117","author":"GJ Barrera","year":"2016","unstructured":"Barrera GJ, Tortolero GS. Trefoil factor 3 (TFF3) from human breast milk activates PAR-2 receptors in the intestinal epithelial cells HT-29, regulating cytokines and defensins. Bratisl Lek Listy. 2016;117:332\u20139.","journal-title":"Bratisl Lek Listy"},{"key":"1040_CR51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.gastro.2009.03.007","volume":"137","author":"DK Podolsky","year":"2009","unstructured":"Podolsky DK, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology. 2009;137:209\u201320.","journal-title":"Gastroenterology"},{"key":"1040_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bbrc.2013.09.049","volume":"440","author":"N Lin","year":"2013","unstructured":"Lin N, Xu LF, Sun M. The protective effect of trefoil factor 3 on the intestinal tight junction barrier is mediated by toll-like receptor 2 via a PI3K\/Akt-dependent mechanism. Biochem Biophys Res Commun. 2013;440:143\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1040_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10753-009-9110-x","volume":"32","author":"X Teng","year":"2009","unstructured":"Teng X, Xu LF, Zhou P, Sun HW, Sun M. Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid-induced colitis mice. Inflammation. 2009;32:120\u20139.","journal-title":"Inflammation"},{"key":"1040_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/634135","volume":"2014","author":"L Shi","year":"2014","unstructured":"Shi L, Zhou PH, Xi JL, Yu HG, Zhang BH. Recombinant human trefoil factor 3 ameliorates bowel injury: its anti-inflammatory effect on experimental necrotizing enterocolitis. Int J Pept. 2014;2014:634135.","journal-title":"Int J Pept"},{"key":"1040_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.arcmed.2019.03.004","volume":"50","author":"Y Wang","year":"2019","unstructured":"Wang Y, Liang K, Kong W. Intestinal trefoil factor 3 alleviates the intestinal barrier function through reducing the expression of TLR4 in Rats with nonalcoholic steatohepatitis. Arch Med Res. 2019;50:2\u20139.","journal-title":"Arch Med Res"},{"key":"1040_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0429-3","volume":"16","author":"V Pandey","year":"2014","unstructured":"Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T, et al. Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res. 2014;16:429.","journal-title":"Breast Cancer Res"},{"key":"1040_CR57","doi-asserted-by":"publisher","first-page":"76770","DOI":"10.18632\/oncotarget.20010","volume":"8","author":"S Diao","year":"2017","unstructured":"Diao S, Zheng Q, Gao J, Yao Y, Ren S, Liu Y, et al. Trefoil factor 3 contributes to the malignancy of glioma via regulating HIF-1\u03b1. Oncotarget. 2017;8:76770\u201382.","journal-title":"Oncotarget"},{"key":"1040_CR58","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.7150\/jca.24361","volume":"9","author":"X Lin","year":"2018","unstructured":"Lin X, Zhang H, Dai J, Zhang W, Zhang J, Xue G, et al. TFF3 contributes to epithelial-mesenchymal transition (EMT) in papillary thyroid carcinoma cells via the MAPK\/ERK signaling pathway. J Cancer. 2018;9:4430\u20139.","journal-title":"J Cancer"},{"key":"1040_CR59","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-021-00677-2","volume":"6","author":"H-Y Cui","year":"2021","unstructured":"Cui H-Y, Wang S-J, Song F, Cheng X, Nan G, Zhao Y, et al. CD147 receptor is essential for TFF3-mediated signaling, regulating colorectal cancer progression. Signal Transduct Target Ther. 2021;6:268.","journal-title":"Signal Transduct Target Ther"},{"key":"1040_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188362","volume":"1873","author":"R Jahan","year":"2020","unstructured":"Jahan R, Shah A, Kisling SG, Macha MA, Thayer S, Batra SK, et al. Odyssey of trefoil factors in cancer: diagnostic and therapeutic implications. Biochim Biophys Acta Rev Cancer. 2020;1873:188362.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1040_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04504-6","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Lin Z, Lin Q, Bei W, Guo J. Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: recent progress and perspective. Cell Death Dis. 2022;13:62.","journal-title":"Cell Death Dis"},{"key":"1040_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/srep30421","volume":"6","author":"Y Sun","year":"2016","unstructured":"Sun Y, Wang L, Zhou Y, Mao X, Deng X. Human trefoil factor 3 induces the transcription of its own promoter through STAT3. Sci Rep. 2016;6:30421.","journal-title":"Sci Rep"},{"key":"1040_CR63","doi-asserted-by":"publisher","first-page":"e0141947","DOI":"10.1371\/journal.pone.0141947","volume":"10","author":"WH Lau","year":"2015","unstructured":"Lau WH, Pandey V, Kong X, Wang XN, Wu Z, Zhu T, et al. Trefoil factor-3 (TFF3) stimulates de novo angiogenesis in mammary carcinoma both directly and indirectly via IL-8\/CXCR2. PLoS ONE. 2015;10:e0141947.","journal-title":"PLoS ONE"},{"key":"1040_CR64","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.193.9.1027","volume":"193","author":"GT Furuta","year":"2001","unstructured":"Furuta GT, Turner JR, Taylor CT, Hershberg RM, Comerford K, Narravula S, et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med. 2001;193:1027\u201334.","journal-title":"J Exp Med"},{"key":"1040_CR65","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1007\/s11033-011-1195-2","volume":"39","author":"B Guleng","year":"2012","unstructured":"Guleng B, Han J, Yang JQ, Huang QW, Huang JK, Yang XN, et al. TFF3 mediated induction of VEGF via hypoxia in human gastric cancer SGC-7901 cells. Mol Biol Rep. 2012;39:4127\u201334.","journal-title":"Mol Biol Rep"},{"key":"1040_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00441-016-2370-5","volume":"365","author":"P Arnold","year":"2016","unstructured":"Arnold P, Rickert U, Helmers AK, Spreu J, Schneppenheim J, Lucius R. Trefoil factor 3 shows anti-inflammatory effects on activated microglia. Cell Tissue Res. 2016;365:3\u201311.","journal-title":"Cell Tissue Res"},{"key":"1040_CR67","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/eji.202048768","volume":"51","author":"J Liu","year":"2021","unstructured":"Liu J, Yang Q, Chen Z, Lv S, Tang J, Xing Z, et al. TFF3 mediates the NF-\u03baB\/COX2 pathway to regulate PMN-MDSCs activation and protect against necrotizing enterocolitis. Eur J Immunol. 2021;51:1110\u201325.","journal-title":"Eur J Immunol"},{"key":"1040_CR68","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.3390\/ijms22094909","volume":"22","author":"W Hoffmann","year":"2021","unstructured":"Hoffmann W. Trefoil factor family (TFF) peptides and their links to inflammation: a re-evaluation and new medical perspectives. Int J Mol Sci. 2021;22:4909.","journal-title":"Int J Mol Sci"},{"key":"1040_CR69","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000522342","volume":"119","author":"F Li","year":"2022","unstructured":"Li F, Hao H, Gao X, Cai Y, Zhou J, Wang D, et al. Potential for CCR9+ IL-17+ regulatory T cell as a predictor of early necrotizing enterocolitis. Neonatology. 2022;119:320\u20136.","journal-title":"Neonatology"},{"key":"1040_CR70","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2217\/fon-2020-1183","volume":"18","author":"L Yang","year":"2022","unstructured":"Yang L, Xiwei Z, Jiyin Z, Yuwei L, Tingting J, Jianing M, et al. Low expression of TFF3 in papillary thyroid carcinoma may correlate with poor prognosis but high immune cell infiltration. Future Oncol. 2022;18:333\u201348.","journal-title":"Future Oncol"},{"key":"1040_CR71","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00384-025-04964-0","volume":"40","author":"X Pan","year":"2025","unstructured":"Pan X, Li J, Zhu J, Wang X, Liu Y, Chen S, et al. Inhibition of TFF3 improves the infiltration and function of CD8+ T cells by downregulating the expression of PD-L1 in colorectal cancer. Int J Colorectal Dis. 2025;40:170.","journal-title":"Int J Colorectal Dis"},{"key":"1040_CR72","doi-asserted-by":"publisher","first-page":"39323","DOI":"10.18632\/oncotarget.16950","volume":"8","author":"ML You","year":"2017","unstructured":"You ML, Chen YJ, Chong QY, Wu MM, Pandey V, Chen RM, et al. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent. Oncotarget. 2017;8:39323\u201344.","journal-title":"Oncotarget"},{"key":"1040_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07387-5","volume":"16","author":"C He","year":"2025","unstructured":"He C, Wang X, Chiou YS, Basappa B, Zhu T, Pandey V, et al. Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma. Cell Death Dis. 2025;16:76.","journal-title":"Cell Death Dis"},{"key":"1040_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024;23:175.","journal-title":"Mol Cancer"},{"key":"1040_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188701","volume":"1877","author":"P Akbari","year":"2022","unstructured":"Akbari P, Katsarou A, Daghighian R, van Mil LWHG, Huijbers EJM, Griffioen AW, et al. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochim Biophys Acta Rev Cancer. 2022;1877:188701.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1040_CR76","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","volume":"14","author":"J Lemoine","year":"2021","unstructured":"Lemoine J, Ruella M, Houot R. Born to survive: how cancer cells resist CAR T cell therapy. J Hematol Oncol. 2021;14:199.","journal-title":"J Hematol Oncol"},{"key":"1040_CR77","unstructured":"Lobie PE, Pandey VK, Subbegowda RK, Dhananjaya MC, RANGAPPA S. Compounds useful in inhibiting human trefoil factor 3. United States patent US 11,141,402. 2021."},{"key":"1040_CR78","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1021\/acsptsci.2c00044","volume":"5","author":"V Pandey","year":"2022","unstructured":"Pandey V, Zhang X, Poh HM, Wang B, Dukanya D, Ma L, et al. Monomerization of homodimeric trefoil factor 3 (TFF3) by an aminonitrile compound inhibits TFF3-dependent cancer cell survival. ACS Pharm Transl Sci. 2022;5:761\u201373.","journal-title":"ACS Pharm Transl Sci"},{"key":"1040_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s43856-024-00710-9","volume":"5","author":"S Chen","year":"2025","unstructured":"Chen S, Zhang X, Basappa B, Zhu T, Pandey V, Lobie PE. TFF3 facilitates dormancy of anti-estrogen-treated ER+ mammary carcinoma. Commun Med. 2025;5:45.","journal-title":"Commun Med"},{"key":"1040_CR80","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1593\/neo.10916","volume":"12","author":"N Kannan","year":"2010","unstructured":"Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, et al. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 2010;12:1041\u201353.","journal-title":"Neoplasia"},{"key":"1040_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70283","volume":"13","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Su M, Jiang P, Wang X, Tong X, Wu G. Unlocking apoptotic pathways: overcoming tumor resistance in CAR-T-cell therapy. Cancer Med. 2024;13:e70283.","journal-title":"Cancer Med"},{"key":"1040_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216443","volume":"579","author":"H Guo","year":"2023","unstructured":"Guo H, Tan YQ, Huang X, Zhang S, Basappa B, Zhu T, et al. Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma. Cancer Lett. 2023;579:216443.","journal-title":"Cancer Lett"},{"key":"1040_CR83","doi-asserted-by":"crossref","unstructured":"Chen RM, Chiou YS, Chong QY, Poh HM, Tan TZ, Zhang MY, et al. Pharmacological inhibition of TFF3 enhances the sensitivity of CMS4 colorectal carcinoma to 5-fluorouracil through inhibition of p44\/42 MAPK. Int J Mol Sci. 2019;20:6215.","DOI":"10.3390\/ijms20246215"},{"key":"1040_CR84","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ncb3090","volume":"17","author":"W Zhou","year":"2015","unstructured":"Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17:170\u201382.","journal-title":"Nat Cell Biol"},{"key":"1040_CR85","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/15384047.2018.1550570","volume":"20","author":"J Wang","year":"2019","unstructured":"Wang J, Wang X, Wang Y, Li S, Wang X. Kr\u00fcppel-like factor 6 splice variant 1 (KLF6-SV1) overexpression recruits macrophages to participate in lung cancer metastasis by up-regulating TWIST1. Cancer Biol Ther. 2019;20:680\u201391.","journal-title":"Cancer Biol Ther"},{"key":"1040_CR86","doi-asserted-by":"publisher","first-page":"892","DOI":"10.7150\/thno.87962","volume":"14","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Tsui YM, Zhang VX, Lu AJ, Lee JM, Lee E, et al. Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma. Theranostics. 2024;14:892\u2013910.","journal-title":"Theranostics"},{"key":"1040_CR87","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1158\/0008-5472.CAN-18-2659","volume":"79","author":"C Shidal","year":"2019","unstructured":"Shidal C, Singh NP, Nagarkatti P, Nagarkatti M. MicroRNA-92 expression in CD133(+) melanoma stem cells regulates immunosuppression in the tumor microenvironment via integrin-dependent activation of TGF\u03b2. Cancer Res. 2019;79:3622\u201335.","journal-title":"Cancer Res"},{"key":"1040_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201901278","volume":"6","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yin K, Tian J, Xia X, Ma J, Tang X, et al. Granulocytic myeloid-derived suppressor cells promote the stemness of colorectal cancer cells through exosomal S100A9. Adv Sci. 2019;6:1901278.","journal-title":"Adv Sci"},{"key":"1040_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1400112","volume":"15","author":"GK Muliawan","year":"2024","unstructured":"Muliawan GK, Lee TK. The roles of cancer stem cell-derived secretory factors in shaping the immunosuppressive tumor microenvironment in hepatocellular carcinoma. Front Immunol. 2024;15:1400112.","journal-title":"Front Immunol"},{"key":"1040_CR90","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41416-024-02676-w","volume":"130","author":"HK Lee","year":"2024","unstructured":"Lee HK, Kim SY, Chung S-H, Choi B, Kim J-E, Yoon D, et al. Tumour-associated myeloid cells expressing IL-10R2\/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma. Br J Cancer. 2024;130:1979\u201389.","journal-title":"Br J Cancer"},{"key":"1040_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00648-z","volume":"12","author":"Z-R Dong","year":"2024","unstructured":"Dong Z-R, Zhang M-Y, Qu L-X, Zou J, Yang Y-H, Ma Y-L, et al. Spatial resolved transcriptomics reveals distinct cross-talk between cancer cells and tumor-associated macrophages in intrahepatic cholangiocarcinoma. Biomark Res. 2024;12:100.","journal-title":"Biomark Res"},{"key":"1040_CR92","first-page":"237","volume":"82","author":"X Wang","year":"2022","unstructured":"Wang X, Qin H. TFF3 promotes pituitary tumor cell migration and angiogenesis via VEGFA. Acta Neurobiol Exp. 2022;82:237\u201343.","journal-title":"Acta Neurobiol Exp"},{"key":"1040_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0173-8","volume":"8","author":"M Zhang","year":"2019","unstructured":"Zhang M, Wang B, Chong Q-Y, Pandey V, Guo Z, Chen R-M, et al. A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1\/2 inhibition in lung adenocarcinoma. Oncogenesis. 2019;8:65.","journal-title":"Oncogenesis"},{"key":"1040_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108690","volume":"112","author":"Z Ghanbari Movahed","year":"2019","unstructured":"Ghanbari Movahed Z, Rastegari-Pouyani M, Mohammadi MH, Mansouri K. Cancer cells change their glucose metabolism to overcome increased ROS: one step from cancer cell to cancer stem cell? Biomed Pharmacother. 2019;112:108690.","journal-title":"Biomed Pharmacother"},{"key":"1040_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5316-y","volume":"19","author":"S Al-Salam","year":"2019","unstructured":"Al-Salam S, Sudhadevi M, Awwad A, Al Bashir M. Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy. BMC Cancer. 2019;19:135.","journal-title":"BMC Cancer"},{"key":"1040_CR96","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ijrobp.2012.01.083","volume":"84","author":"E Casado","year":"2012","unstructured":"Casado E, Garc\u00eda VM, S\u00e1nchez JJ, G\u00f3mez Del Pulgar MT, Feliu J, Maurel J, et al. Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target. Int J Radiat Oncol Biol Phys. 2012;84:1151\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1040_CR97","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canlet.2015.02.051","volume":"361","author":"O Perera","year":"2015","unstructured":"Perera O, Evans A, Pertziger M, MacDonald C, Chen H, Liu DX, et al. Trefoil factor 3 (TFF3) enhances the oncogenic characteristics of prostate carcinoma cells and reduces sensitivity to ionising radiation. Cancer Lett. 2015;361:104\u201311.","journal-title":"Cancer Lett"},{"key":"1040_CR98","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2014mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39\u201351.","journal-title":"N Engl J Med"},{"key":"1040_CR99","doi-asserted-by":"publisher","first-page":"74188","DOI":"10.18632\/oncotarget.18431","volume":"8","author":"QY Chong","year":"2017","unstructured":"Chong QY, You ML, Pandey V, Banerjee A, Chen YJ, Poh HM, et al. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+\/ER+ mammary carcinoma. Oncotarget. 2017;8:74188\u2013208.","journal-title":"Oncotarget"},{"key":"1040_CR100","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.molcel.2012.06.014","volume":"47","author":"H Korkaya","year":"2012","unstructured":"Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47:570\u201384.","journal-title":"Mol Cell"},{"key":"1040_CR101","doi-asserted-by":"publisher","first-page":"16057","DOI":"10.1074\/jbc.M113.529552","volume":"289","author":"K Ding","year":"2014","unstructured":"Ding K, Banerjee A, Tan S, Zhao J, Zhuang Q, Li R, et al. Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells. J Biol Chem. 2014;289:16057\u201371.","journal-title":"J Biol Chem"},{"key":"1040_CR102","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10549-019-05445-z","volume":"179","author":"JP Leone","year":"2020","unstructured":"Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, et al. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020;179:113\u201323.","journal-title":"Breast Cancer Res Treat"},{"key":"1040_CR103","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1634\/theoncologist.2020-0127","volume":"25","author":"J Xu","year":"2020","unstructured":"Xu J, Higgins MJ, Tolaney SM, Come SE, Smith MR, Fornier M, et al. A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases. Oncologist. 2020;25:652\u201360.","journal-title":"Oncologist"},{"key":"1040_CR104","doi-asserted-by":"publisher","first-page":"e25962","DOI":"10.4161\/onci.25962","volume":"2","author":"MH Kershaw","year":"2013","unstructured":"Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology. 2013;2:e25962.","journal-title":"Oncoimmunology"},{"key":"1040_CR105","doi-asserted-by":"crossref","unstructured":"Jarosz-Biej M, Smolarczyk R, Cicho\u0144 T, Ku\u0142ach N. Tumor microenvironment as a \u201cGame Changer\u201d in cancer radiotherapy. Int J Mol Sci. 2019;20:3212.","DOI":"10.3390\/ijms20133212"},{"key":"1040_CR106","doi-asserted-by":"crossref","unstructured":"Merlano MC, Denaro N, Galizia D, Ruatta F, Occelli M, Minei S, et al. How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review. Biomedicines. 2022;10.","DOI":"10.3390\/biomedicines10081822"},{"key":"1040_CR107","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1097\/CM9.0000000000002535","volume":"136","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Peng Y, Peng X, Xiao D, Shi Y, Tao Y. Effects of radiation therapy on tumor microenvironment: an updated review. Chin Med J. 2023;136:2802\u201311.","journal-title":"Chin Med J"},{"key":"1040_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1140541","volume":"14","author":"AX Wang","year":"2023","unstructured":"Wang AX, Ong XJ, D\u2019Souza C, Neeson PJ, Zhu JJ. Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Front Immunol. 2023;14:1140541.","journal-title":"Front Immunol"},{"key":"1040_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116532","volume":"174","author":"W Szlasa","year":"2024","unstructured":"Szlasa W, Sztuder A, Kaczmar-Dybko A, Maciejczyk A, Dybko J. Efficient combination of radiotherapy and CAR-T\u2014a systematic review. Biomed Pharmacother. 2024;174:116532.","journal-title":"Biomed Pharmacother"},{"key":"1040_CR110","doi-asserted-by":"publisher","first-page":"21247","DOI":"10.18632\/oncotarget.6918","volume":"7","author":"M Arjaans","year":"2016","unstructured":"Arjaans M, Schr\u00f6der CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EG. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget. 2016;7:21247\u201358.","journal-title":"Oncotarget"},{"key":"1040_CR111","doi-asserted-by":"crossref","unstructured":"Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S, et al. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J Immunother Cancer. 2023;11:e005583.","DOI":"10.1136\/jitc-2022-005583"},{"key":"1040_CR112","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1111\/cas.15074","volume":"112","author":"A Tomida","year":"2021","unstructured":"Tomida A, Yagyu S, Nakamura K, Kubo H, Yamashima K, Nakazawa Y, et al. Inhibition of the MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. Cancer Sci. 2021;112:4026\u201336.","journal-title":"Cancer Sci"},{"key":"1040_CR113","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.gastro.2003.12.004","volume":"126","author":"PL Beck","year":"2004","unstructured":"Beck PL, Wong JF, Li Y, Swaminathan S, Xavier RJ, Devaney KL, et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology. 2004;126:796\u2013808.","journal-title":"Gastroenterology"},{"key":"1040_CR114","doi-asserted-by":"publisher","first-page":"13418","DOI":"10.1074\/jbc.M800177200","volume":"283","author":"FP Paulsen","year":"2008","unstructured":"Paulsen FP, Woon CW, Varoga D, Jansen A, Garreis F, J\u00e4ger K, et al. Intestinal trefoil factor\/TFF3 promotes re-epithelialization of corneal wounds. J Biol Chem. 2008;283:13418\u201327.","journal-title":"J Biol Chem"},{"key":"1040_CR115","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4161\/rna.8.1.13687","volume":"8","author":"AA Shah","year":"2011","unstructured":"Shah AA, Leidinger P, Keller A, Wendschlag A, Backes C, Baus-Loncar M, et al. The intestinal factor Tff3 and a miRNA network regulate murine caloric metabolism. RNA Biol. 2011;8:77\u201381.","journal-title":"RNA Biol"},{"key":"1040_CR116","doi-asserted-by":"publisher","first-page":"E436","DOI":"10.1152\/ajpendo.00454.2018","volume":"317","author":"X Wu","year":"2019","unstructured":"Wu X, Zheng H, Yang R, Luan X, Zhang L, Jin Q, et al. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-\u03b1-mediated fatty acid oxidation. Am J Physiol Endocrinol Metab. 2019;317:E436\u2013e45.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1040_CR117","doi-asserted-by":"publisher","first-page":"e77732","DOI":"10.1371\/journal.pone.0077732","volume":"8","author":"SQ Liu","year":"2013","unstructured":"Liu SQ, Roberts D, Zhang B, Ren Y, Zhang LQ, Wu YH. Trefoil factor 3 as an endocrine neuroprotective factor from the liver in experimental cerebral ischemia\/reperfusion injury. PLoS ONE. 2013;8:e77732.","journal-title":"PLoS ONE"},{"key":"1040_CR118","doi-asserted-by":"crossref","unstructured":"Kozina N, Mihaljevi\u0107 Z, Lon\u010dar MB, Mihalj M, Mi\u0161ir M, Radmilovi\u0107 MD, et al. Impact of high salt diet on cerebral vascular function and stroke in Tff3(-\/-)\/C57BL\/6N knockout and WT (C57BL\/6N) control mice. Int J Mol Sci. 2019;20:5188.","DOI":"10.3390\/ijms20205188"},{"key":"1040_CR119","doi-asserted-by":"publisher","first-page":"15549","DOI":"10.1073\/pnas.0707461104","volume":"104","author":"DW Bartlett","year":"2007","unstructured":"Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA. 2007;104:15549\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1040_CR120","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.18632\/oncotarget.7076","volume":"7","author":"MC Palanca-Wessels","year":"2016","unstructured":"Palanca-Wessels MC, Booth GC, Convertine AJ, Lundy BB, Berguig GY, Press MF, et al. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells. Oncotarget. 2016;7:9561\u201375.","journal-title":"Oncotarget"},{"key":"1040_CR121","doi-asserted-by":"crossref","unstructured":"Jiang X, Abedi K, Shi J. Polymeric nanoparticles for RNA delivery. In: Yin Y, Lu Y, Xia Y, editors. Encyclopedia of Nanomaterials (1st edn). Oxford: Elsevier; 2023.","DOI":"10.1016\/B978-0-12-822425-0.00017-8"},{"key":"1040_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02283-z","volume":"23","author":"M Safarzadeh","year":"2025","unstructured":"Safarzadeh M, Saadat N, Abbasi-Molaei S, Rastegari-Pouyani M. Extracellular vesicles as missiles for enhanced anti-tumor efficacy of oncolytic viruses: from disseminating oncolysis and anti-tumor immunity to targeted delivery. Cell Commun Signal. 2025;23:276.","journal-title":"Cell Commun Signal"},{"key":"1040_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1447953","volume":"11","author":"P Ubanako","year":"2024","unstructured":"Ubanako P, Mirza S, Ruff P, Penny C. Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges. Front Mol Biosci. 2024;11:1447953.","journal-title":"Front Mol Biosci"},{"key":"1040_CR124","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.addr.2016.02.006","volume":"106","author":"P Vader","year":"2016","unstructured":"Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106:148\u201356.","journal-title":"Adv Drug Deliv Rev"},{"key":"1040_CR125","doi-asserted-by":"crossref","unstructured":"Garofalo M, Villa A, Rizzi N, Kuryk L, Mazzaferro V, Ciana P. Systemic administration and targeted delivery of immunogenic oncolytic adenovirus encapsulated in extracellular vesicles for cancer therapies. Viruses. 2018;10:558.","DOI":"10.3390\/v10100558"},{"key":"1040_CR126","doi-asserted-by":"crossref","unstructured":"Kang S, Lee S, Park S. iRGD peptide as a tumor-penetrating enhancer for tumor-targeted drug delivery. Polymers. 2020;12:1906.","DOI":"10.3390\/polym12091906"},{"key":"1040_CR127","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s10620-020-06262-x","volume":"66","author":"L Xin","year":"2021","unstructured":"Xin L, Yuan YW, Liu C, Zhou LQ, Liu L, Zhou Q, et al. Preparation of internalizing RGD-modified recombinant methioninase exosome active targeting vector and antitumor effect evaluation. Dig Dis Sci. 2021;66:1045\u201353.","journal-title":"Dig Dis Sci"},{"key":"1040_CR128","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01040-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01040-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01040-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:04:48Z","timestamp":1782824688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01040-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1040"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01040-9","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}